{"filings":[{"id":2244119,"accession_number":"0001193125-26-349170","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2026-08-13T20:08:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q2 net loss $31.6M; cash $88.8M; Phase 3 kidney trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $88.8M at June 30, 2026 vs $133.3M at Dec 31, 2025; expected to fund ops into Q2 2027.","Q2 net loss $31.6M ($0.27/share) vs $11.2M ($0.13) prior year; ex-warrant changes, loss $22.0M vs $23.5M.","FDA End-of-Phase 2 meeting supports Phase 3 kidney transplant trial of tegoprubart; ~600 patients, late 2026 start.","BESTOW 18-month data: eGFR ~12 mL/min higher vs tacrolimus (74 vs 61); no BPAR after 6 months in tegoprubart arm.","Islet cell study: all 12 T1D patients insulin-independent, mean HbA1c ~5.4%; Natera Prospera partnership for Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1196961,"accession_number":"0001193125-26-277653","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2026-06-22T21:00:16+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Eledon stockholders approve increase in authorized common shares from 300M to 450M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class III directors: David-Alexandre C. Gros, M.D., Jan Hillson, M.D., James Robinson for terms ending 2029.","Authorized share increase approved with 52.3M for, 3.7M against, 294k abstain.","Ratified Deloitte & Touche as independent auditor for FY 2026.","Certificate of Amendment effective June 22, 2026, filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68401,"accession_number":"0001193125-26-221658","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2026-05-13T20:15:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.","Net loss $39.0M ($0.33/share) vs $6.5M ($0.08/share) in Q1 2025; includes $19M non-cash loss from warrant liabilities.","R&D expense $17.2M (incl. $1.1M stock comp) vs $13.5M in prior year; G&A $4.0M vs $4.4M.","10/10 evaluable patients achieved 100% insulin independence with tegoprubart in islet transplantation; no rejection or tacrolimus-like toxicities.","FDA granted Orphan Drug designation for tegoprubart in liver transplantation; Phase 3 kidney trial design guidance expected from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103647,"accession_number":"0001193125-26-116154","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon FY2025 net loss $45.6M; tegoprubart data shows insulin independence in T1D islet transplant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $45.6M ($0.52/share) vs $36.2M loss in FY2024; non-GAAP net loss (excl warrant gain) was $79.1M.","R&D expenses rose to $66.3M from $52.0M, driven by clinical trial expansion and manufacturing scale-up.","Phase 1b kidney transplant data: eGFR improved from 67.0 at 12mo to 74.2 at 24mo; no rejection or graft loss in 8 patients.","In T1D islet transplant study, all 10 patients >4 weeks post-transplant achieved 100% insulin independence with mean HbA1c ~5.35%.","Tegoprubart received FDA Orphan Drug designation for liver transplantation; Phase 3 kidney trial initiation pending FDA guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103646,"accession_number":"0001193125-26-000968","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Eledon exchanges 4.2M shares for pre-funded warrant with Coastlands","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchange of 4,203,764 common shares for pre-funded warrant at $0.001 exercise price.","Warrant has 4.99% beneficial ownership limitation, can be increased to 19.99% per Nasdaq rules.","Issued under Section 3(a)(9) exemption; exchange closed December 30, 2025.","Counterparty: Coastlands Capital Partners LP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119911,"accession_number":"0001193125-25-283294","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.","Cash & investments $93.4M at Sep 30, down from $140.2M at Dec 31, 2024.","Phase 2 BESTOW: tegoprubart showed favorable safety, eGFR ~69 at 12 months; plans Phase 3 in 2026.","Completed $57.5M public offering on Nov 13, net proceeds ~$53.6M to advance transplant programs.","Anticipates FDA guidance on Phase 3 trial design for kidney transplantation in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119910,"accession_number":"0001193125-25-278392","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eledon raises ~$46.5M in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 15.15M shares at $1.65/share and up to 15.15M pre-funded warrants at $1.649/warrant.","Net proceeds estimated at $46.5M; up to $53.6M if underwriters' 30-day option is fully exercised.","Proceeds to fund clinical development of product candidates and for general corporate purposes.","Underwriters granted 30-day option to purchase up to 4.55M additional shares of common stock.","Company and certain insiders subject to 60-day lock-up on sales of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119909,"accession_number":"0001193125-25-270286","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Eledon Phase 2 BESTOW trial: tegoprubart eGFR 69 vs tacrolimus 66, primary endpoint not met but safety superior","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary efficacy endpoint (eGFR at 12 months) did not reach statistical significance: 69 vs 66 mL/min/1.73 m².","New-onset diabetes 1/47 on tegoprubart vs ~1/6 on tacrolimus; tremor 1.6% vs 25.0%; delayed graft function 14.3% vs 25.0%.","Efficacy failure composite (death, graft loss, BPAR) was 22% tegoprubart vs 17% tacrolimus, meeting non-inferiority margin.","Cash, equivalents, and short-term investments approximately $93.4M as of Sept 30, 2025, expected to fund operations to late 2026.","Company plans to advance tegoprubart into Phase 3 after regulatory discussions on study design and data requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136480,"accession_number":"0001193125-25-180820","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.","Identified a material weakness in internal control over financial reporting related to accounting for equity instruments; controls and disclosure controls were not effective.","Reported Q2 2025 net loss of $11.2 million ($0.13 per share) and cash and short-term investments of $107.6 million as of June 30, 2025.","Updated Phase 1b data for tegoprubart showed mean 12-month eGFR of ~68 mL/min/1.73m²; Phase 2 BESTOW topline expected November 2025.","Company expects current cash to fund operations to the end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136479,"accession_number":"0000950170-25-103975","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eledon reports updated Phase 1b data for tegoprubart; eGFR ~68 at 12 months, predicted 5-year graft survival >96%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².","Preliminary abbreviated iBox score -4.11 (on-treatment) vs -2.98 historical CNI; predicts 5-year graft survival >96%.","No deaths, graft loss, drug-related tremor, or new-onset diabetes; six rejection episodes (18.8%), all successfully treated.","Patients who remained on tegoprubart after rejection had mean eGFR ~73 mL/min/1.73m² at 12 months; switched to tacrolimus had ~34.","Topline results from Phase 2 BESTOW trial comparing tegoprubart to tacrolimus expected in November 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153636,"accession_number":"0000950170-25-085588","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Eledon shareholders approve increase in authorized common shares to 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in authorized common stock from 200M to 300M shares (40.79M for, 0.49M against).","Approved amendment to extend officer exculpation protection to fullest extent under Delaware law (30.04M for, 1.29M against).","Elected Class II directors Keith Katkin, Allan Kirk, and John McBride for three-year terms ending 2028.","Ratified Deloitte & Touche as independent auditor for FY2025 (41.31M for, 36k against).","Authorized share increase and officer exculpation amendments became effective June 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153635,"accession_number":"0000950170-25-071370","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.","Cash, equivalents and short-term investments $124.9M as of March 31, 2025; funds operations to end of 2026.","R&D expenses $13.5M (incl. $1.0M SBC) vs $7.4M prior year; G&A $4.4M vs $3.5M.","Tegoprubart used in second genetically modified pig kidney transplant at Mass General; patient discharged without dialysis.","Topline Phase 2 BESTOW results on track for Q4 2025; interim Phase 1b data expected August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153633,"accession_number":"0000950170-25-053765","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K/A","filed_at":"2025-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals amends 8-K to correct auditor dismissal period; Crowe served only FY 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects prior 8-K that inadvertently referenced Crowe LLP for fiscal year 2023.","Audit Committee dismissed Crowe LLP and engaged Deloitte & Touche LLP on April 1, 2025.","Crowe served as auditor from July 10, 2024 to April 1, 2025; no disagreements or reportable events.","Deloitte engaged as independent auditor for fiscal year ending December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153634,"accession_number":"0000950170-25-051663","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals dismisses Crowe LLP, appoints Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Crowe LLP as independent auditor effective April 1, 2025.","No disagreements or reportable events in fiscal years 2023 and 2024 or interim period.","Crowe's audit reports for 2023 and 2024 were unqualified and not modified.","Deloitte & Touche LLP appointed as new auditor for fiscal year ending Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172338,"accession_number":"0000950170-25-042644","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.","FY 2024 net loss $36.2M vs $116.5M in 2023; excluding warrant changes, net loss $67.1M vs $40.3M.","Cash $140.2M at Dec 31, 2024; $85M oversubscribed offering extends runway to end of 2026.","Tegoprubart used in second genetically modified pig kidney transplant (Jan 25, 2025) at Mass General; patient off dialysis.","Positive initial data on islet transplant recipients; insulin independence without tacrolimus; topline Ph2 BESTOW due Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189341,"accession_number":"0000950170-24-138782","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eledon amends CEO Performance Bonus; increases max payout to $15M at $1.5B market cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David-Alexandre Gros' employment agreement amended to modify Performance Bonus market value cap.","Bonus threshold of $6M at $600M market cap remains unchanged.","Maximum bonus increased to $15M at $1.5B market cap using linear interpolation.","Agreement entered Dec 16, 2024; filed Dec 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189340,"accession_number":"0000950170-24-125340","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon completes BESTOW enrollment early; reports $77M net income on non-cash gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 BESTOW trial for tegoprubart in kidney transplant hit target of 120 patients ~4 months ahead of schedule.","First two islet transplant recipients with type 1 diabetes achieved insulin independence on tegoprubart without tacrolimus.","Completed oversubscribed $85M offering in October; net proceeds ~$79.5M extend cash runway to end of 2026.","Q3 2024 net income $77M ($1.05 basic EPS) includes $96.4M non-cash fair value gain; adjusted net loss $19.5M.","Cash and short-term investments $78.2M at Sep 30, 2024; R&D expenses rose to $16.5M from $7.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189339,"accession_number":"0000950170-24-118497","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals prices $85M offering of common stock and pre-funded warrants at $3.65/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$85M; net proceeds ~$79.5M after underwriting discounts and expenses.","Offering: 18,356,173 common shares at $3.65 plus pre-funded warrants for 4,931,507 shares at $3.649.","Investors include BVF Partners, RA Capital, Frazier Life Sciences, Blue Owl, First Light, Sphera, Woodline, Nantahala, and T1D Fund.","Proceeds to be used for advancing pipeline, working capital, and general corporate purposes.","Closing expected on or about October 30, 2024; 90-day lock-up for executives and directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189338,"accession_number":"0000950170-24-117946","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eledon's tegoprubart enables insulin independence in first two islet transplant recipients with T1D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First two subjects achieved insulin independence post-transplant; third subject on trajectory with >60% insulin reduction at day 3.","Islet engraftment 3-5x higher than comparable subjects on tacrolimus-based immunosuppression, suggesting less toxicity to transplanted cells.","Treatment was generally well tolerated with no unexpected adverse events or severe hypoglycemic episodes.","Data to be presented at IPITA/HSCI/Breakthrough T1D Stem Cells Summit on Oct 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189337,"accession_number":"0000950170-24-110857","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Eledon Pharmaceuticals raises ~$4M via private placement of 1.727M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,527,400 shares on Sept 30 and 200,000 shares on Oct 1, 2024.","Gross proceeds of approximately $4.0 million from the sale.","Shares issued under Securities Purchase Agreement dated April 28, 2023.","Offering exempt from registration under Section 4(a)(2) and Rule 506(b).","Proceeds intended for general corporate purposes; no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205841,"accession_number":"0000950170-24-108465","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals enters $75M at-the-market equity facility with Guggenheim Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM sales agreement with Guggenheim Securities for up to $75M in common stock sales.","Shares sold directly on Nasdaq under Rule 415; 3.0% gross proceeds commission to Guggenheim.","Company may terminate agreement with ten trading days' notice; no obligation to sell.","Shelf registration statement on Form S-3 filed concurrently; subject to SEC effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205840,"accession_number":"0000950170-24-097206","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Eledon restates financials due to warrant misclassification; reports $83.6M cash and Phase 2 progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on FY2023 and Q1 2024 financials due to warrant derivative accounting error; expects restatement and amendments.","Ended Q2 with $83.6M cash, including $50M private placement; expects liquidity through December 2025.","Phase 2 BESTOW trial enrolled 80th participant, on track to complete enrollment by end of 2024.","Phase 1b data from 13 kidney transplant patients showed mean eGFR 70.5; two patients >90 at one year.","Identified material weakness in internal control over financial reporting; restatement is non-cash and does not affect operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205839,"accession_number":"0000950170-24-083220","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals replaces auditor KMJ Corbin with Crowe LLP; no disagreements reported","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed KMJ Corbin and appointed Crowe LLP on July 10, 2024, after KMJ partners joined Crowe.","KMJ's reports for fiscal years 2022 and 2023 contained no adverse opinion but included a going concern explanatory paragraph.","No disagreements or reportable events occurred during the two most recent fiscal years and subsequent interim period.","KMJ provided a letter agreeing with the company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205838,"accession_number":"0000950170-24-082739","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Eledon Pharmaceuticals completes $2.1M unregistered stock sale of 909,088 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 909,088 shares of common stock in second closing under Securities Purchase Agreement dated April 28, 2023.","Gross proceeds of approximately $2.1 million from institutional and accredited investors.","Exempt from registration under Section 4(a)(2) and Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205837,"accession_number":"0000950170-24-082730","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Eledon shareholders approve 3.5M share increase to 2020 incentive plan; director Ogier retires, committees reshuffled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2020 Long Term Incentive Plan, increasing share reserve by 3.5M to 17.96M shares and extending grant period to May 2034.","Class I directors Steven Perrin and June Lee elected to three-year terms with 18.4M and 17.3M votes for, respectively.","Walter Ogier retired from board effective July 10; Audit, Compensation, and Nominating committees restructured with new members.","KMJ Corbin & Company LLP ratified as independent auditor for fiscal 2024 with 23.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222828,"accession_number":"0000950170-24-058706","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.","Cash, cash equivalents & short-term investments $42.9M at quarter end, excluding $50M private placement.","Completed oversubscribed $50M private placement at $2.37/share with institutional investors.","First patient dosed in investigator-led islet cell transplant trial with tegoprubart for type 1 diabetes.","Phase 2 BESTOW trial (tegoprubart vs tacrolimus) enrolled 12th participant; full enrollment expected end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222827,"accession_number":"0000950170-24-053934","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Eledon raises $50M in oversubscribed private placement; tegoprubart advances in transplant trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$50M from 13.1M shares at $2.37/sh and 7.99M pre-funded warrants at $0.001/sh.","Financing led by BVF Partners; expected to close week of May 6; net proceeds for pre-commercial activities and tegoprubart development.","First participant dosed in islet cell transplant trial with tegoprubart for type 1 diabetes at University of Chicago.","Updated Phase 1b kidney transplant data: mean eGFR >60 mL/min after day 30; two subjects at 12 months had eGFR >90.","No graft loss or death in Phase 1b; three discontinuations (hair loss/fatigue, viral infection, rejection)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242305,"accession_number":"0000950170-24-038008","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).","Cash and equivalents $51.1M as of Dec 31, 2023; down from $56.4M year-end 2022.","12 participants enrolled in Phase 2 BESTOW trial of tegoprubart vs tacrolimus in kidney transplant.","Phase 1b data (n=11) showed tegoprubart safe, with eGFR >70 mL/min at all post-90-day time points.","Tegoprubart used in first pig-to-human kidney xenotransplant on March 16, 2024 at Massachusetts General Hospital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259707,"accession_number":"0000950170-23-062007","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon reports Q3 net loss $10.3M ($0.35/sh); cash $59.6M; advances tegoprubart trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.3M ($0.35 per share) vs $10.5M ($0.73) YoY; R&D spend $7.9M.","Cash & short-term investments $59.6M as of Sept 30, 2023, up from $56.4M at Dec 31, 2022.","Phase 1b data: tegoprubart prevented kidney transplant rejection; mean eGFR >70 at all post-Day 90 timepoints.","First participant dosed in Phase 2 BESTOW trial for kidney transplant rejection; enrollment completion targeted end of 2024.","Tegoprubart used in second-ever pig-to-human heart transplant; appointed new CMO (Eliezer Katz) and two board members."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259706,"accession_number":"0000950170-23-058279","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eledon reports Phase 1b data: tegoprubart prevents rejection with eGFR >70 in kidney transplant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data from 11 participants showed no graft loss or death; one mild T cell mediated rejection (Banff 1a) on day 99 treated successfully.","Aggregate mean eGFR above 70 mL/min/1.73m2 after day 90; no hyperglycemia, new onset diabetes, tremor, or CMV infection seen.","Phase 2 BESTOW trial comparing tegoprubart vs. tacrolimus underway; enrollment of ~120 participants expected to complete end of 2024.","One participant completed 1-year study with eGFR of 91 at day 374 and enrolled in Phase 2 open-label extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259705,"accession_number":"0000950170-23-050925","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eledon Pharmaceuticals appoints Dr. Allan Douglas Kirk to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands from 8 to 9 directors; Dr. Kirk effective Oct 2, 2023.","Determined independent under Nasdaq rules; will serve on Science and Technology Committee.","Annual cash retainers: $42,000 for board service, $7,875 for committee service.","Granted option for 150,437 shares at market price on Oct 2, 2023; vests over 2 years.","Enters standard indemnification agreement for directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276975,"accession_number":"0000950170-23-049046","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eledon Pharmaceuticals adopts updated director and officer indemnification agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved new form of indemnification agreement for all directors and officers.","Agreement provides indemnification to the maximum extent permitted by Delaware law.","New agreement replaces existing indemnification agreements in place with directors and executive officers.","No departures, elections, or appointments of officers were announced.","Indemnification rights are in addition to any rights under certificate of incorporation or bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276974,"accession_number":"0000950170-23-047951","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eledon Pharmaceuticals appoints James Robinson to board effective Oct 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robinson will serve as chair of the Compensation Committee and member of Audit Committee.","Annual cash retainers of $42k for board service, $15.75k as comp chair, $10.5k for audit committee.","Granted option to purchase 150,437 shares vesting over two years at market price on grant date.","Board determined Robinson qualifies as independent under Nasdaq rules; no family relationships or arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276973,"accession_number":"0000950170-23-040949","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon reports Q2 net loss $9.6M; cash $71.4M; raises up to $185M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($0.40 per share) in Q2 2023 vs $9.2M ($0.65 per share) in Q2 2022.","Cash and short-term investments totaled $71.4M at June 30, 2023, up from $56.4M at Dec 31, 2022.","Closed financing worth up to $185M, including $35M upfront, to fund through Phase 2 BESTOW trial.","Ninth patient dosed in Phase 1b kidney transplant trial; updated data expected Q4 2023.","Preclinical study shows subcutaneous tegoprubart formulation safe with similar blood levels."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294831,"accession_number":"0000950170-23-029259","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Eledon shareholders approve 9.6M share increase to 2020 incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2020 Long Term Incentive Plan: share reserve raised from 4.86M to 14.46M shares.","Two Class III directors re-elected: David-Alexandre C. Gros and Jan Hillson (each ~7.1M for votes).","Advisory say-on-pay passed with 7.05M for vs 234K against; auditor KMJ Corbin ratified with 9.62M for.","Plan extended through April 26, 2033; additional 9.6M shares approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294830,"accession_number":"0000950170-23-021198","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon reports Q1 net loss $10.8M; clinical and financing updates on tegoprubart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.8M ($0.75/share) vs $9.9M ($0.69) in Q1 2022; R&D expenses rose to $8.1M.","Cash $46.5M at March 31; second-quarter financing provided $35M upfront (up to $185M) to fund Phase 2 BESTOW.","Phase 1b kidney transplant data (3 patients): no acute rejection; mean eGFR >70 mL/min/1.73m2 at timepoints up to 31 weeks.","Phase 2a IgAN study: tegoprubart safe and well tolerated; no serious/severe AEs; 4 patients completed ≥24 weeks.","Phase 2 BESTOW trial expected to initiate mid-2023; updated Phase 1b data anticipated late 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294829,"accession_number":"0000950170-23-016017","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Eledon secures up to $185M financing led by BVF and Armistice for tegoprubart kidney transplant trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $35M private placement (15.2M shares + warrants at $2.31/share); potential $105M milestone tranches and $45M warrant exercise.","Lead placement agent SVB Securities; co-agents Cantor, LifeSci Capital, Noble Capital Markets.","CEO Dr. Gros gets amended retention bonus: pro-rata $6M–$10M if market value >=$600M; additional equity incentives tied to milestones.","Board director Gary Lyons retiring at 2023 annual meeting; not standing for re-election.","Proceeds to fund Phase 2 BESTOW trial evaluating tegoprubart in kidney transplant rejection prevention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315413,"accession_number":"0000950170-23-010924","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon reports Q4 2022 net loss of $58.4M, including $48.6M goodwill impairment; refocuses on kidney transplant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $58.4M ($4.09/share) vs $8.8M ($0.59) in Q4 2021; full-year net loss $88.0M ($6.16) vs $34.5M ($2.33).","Cash and equivalents $56.4M at Dec 31, 2022; expected to fund operations into Q1 2024.","Phase 1b kidney transplant trial dosed fourth patient; data on first three to be presented at WCN March 31, 2023.","Deprioritized IgAN program and discontinued islet cell trial; collaboration with eGenesis for xenotransplantation.","Subject to financing, Phase 2 BESTOW trial of tegoprubart in kidney transplant expected to initiate mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315412,"accession_number":"0000950170-23-000465","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eledon prioritizes kidney transplant program for tegoprubart; Phase 1b data expected Q1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ph 1b kidney transplant trial enrollment ongoing; initial 3- and 6-month data at World Congress of Nephrology March 2023.","FDA cleared IND for Phase 2 BESTOW trial (tegoprubart vs tacrolimus, ~120 patients); site initiation mid-2023.","Deprioritizing tegoprubart in IgAN and discontinuing islet cell trial to focus resources on kidney transplantation.","Cash resources sufficient to fund operating activities into 2024 (no specific amount given).","Collaboration with eGenesis for preclinical xenotransplantation studies using tegoprubart."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333762,"accession_number":"0000950170-22-024980","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon reports Q3 net loss $10.5M; advances tegoprubart with FDA IND clearances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.5M ($0.73/share) vs $9.8M ($0.66/share) in Q3 2021.","Cash and equivalents $65.9M as of Sep 30, 2022; runway into 2024.","FDA cleared IND for Phase 2 trial of tegoprubart in kidney transplant prevention.","FDA cleared IND for tegoprubart in IgA Nephropathy; global Phase 2a enrolling.","Initial data from kidney, islet cell, and IgAN studies expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351223,"accession_number":"0000950170-22-016850","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q2 net loss $9.2M; advances tegoprubart trials across kidney, IgAN, ALS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.2M ($0.65 per share) vs $7.4M loss in Q2 2021.","Cash at $70.5M; management expects to fund operations into 2024.","FDA cleared IND for Phase 2 kidney transplant trial; first patient dosed in Phase 1b ex-US kidney study.","Positive Phase 2a ALS topline: tegoprubart met safety endpoints; showed target engagement and biomarker reduction.","Orphan Drug Designation granted for tegoprubart in islet cell transplantation; IgAN trial enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368549,"accession_number":"0000950170-22-011978","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eledon Pharmaceuticals annual meeting elects directors and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Keith A. Katkin (7,330,714 for, 765,231 withhold) and John S. McBride (7,287,222 for, 808,723 withhold) as Class II directors for term ending 2025.","Ratified KMJ Korbin & Company LLP as independent auditor for FY2022 with 10,173,336 for, 10,380 against, 3,433 abstain.","All proposals passed at the June 21, 2022 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368548,"accession_number":"0000950170-22-010890","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Eledon reports positive Phase 2a topline results for tegoprubart in ALS patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tegoprubart met primary safety and tolerability endpoints; no drug-related serious adverse events observed.","Dose-dependent target engagement at 4 and 8 mg/kg; anti-drug antibodies in <5% of samples, low titer.","Pro-inflammatory ALS signature of 32 biomarkers identified; dose-dependent reduction in up to 23 biomarkers.","Trend in slowing ALS progression (ALSFRS slope) vs. PRO-ACT database; study not powered for efficacy.","Reduced biomarkers also associated with IgA nephropathy and kidney transplant rejection (IgA, C3, CXCL9, etc.)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368547,"accession_number":"0001564590-22-019851","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Pharma Q1 net loss $9.9M; ALS topline data expected June 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.9M ($0.69/diluted share) vs $8.5M ($0.57) in Q1 2021.","Cash $76.7M as of March 31, 2022, down from $84.8M; runway into 2024.","Phase 2a ALS trial fully enrolled; topline data anticipated in June 2022.","First patient dosed in Phase 2a IgA Nephropathy trial; initial data late 2022.","Non-human primate study of tegoprubart monotherapy in kidney allograft rejection completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387812,"accession_number":"0001564590-22-011680","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Pharma reports FY2021 net loss of $34.5M; cash $84.8M into 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2021 was $8.8M ($0.59/share); FY2021 net loss $34.5M ($2.33/share).","R&D expense rose to $23.7M in FY2021 from $6.1M in FY2020, driven by tegoprubart trials.","Cash and equivalents $84.8M at Dec 31, 2021, down from $114.2M a year earlier.","Topline Phase 2a tegoprubart data in ALS expected in Q2 2022; kidney, IgAN, islet data in Q4 2022.","No revenue recorded; net loss widened due to increased clinical development costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387811,"accession_number":"0001564590-22-001203","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2022-01-13T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Eledon exchanges 550K common for Series X1 preferred; convertible at 55.56 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 550,000 common shares for 9,899.99 Series X1 preferred shares with BVF entities.","Series X1 preferred convertible into ~6.55M shares at 55.5556 common per preferred (post-reverse split).","After exchange, common outstanding: 13,756,788; Series X1 preferred outstanding: ~117,970 shares.","Exchange exempt under Section 3(a)(9) of Securities Act; no registration required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405744,"accession_number":"0001564590-21-056413","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon Q3 net loss of $9.8M ($0.66/sh); pipeline progress in ALS, IgAN, transplant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.8M for Q3 2021 vs $6.1M; R&D expenses surged to $7.7M from $0.6M.","Cash of $94.0M as of Sept 30, 2021; company funded into 2023.","Phase 2 ALS study nearing full enrollment; topline data expected 1H 2022.","IND clearance for AT-1501 in islet cell transplantation; kidney and IgAN trials expected Q4 2021 start.","Research collaboration with CareDx for renal transplant biomarkers and predictive algorithms."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424780,"accession_number":"0001564590-21-043944","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eledon posts Q2 net loss $7.4M; advances AT-1501 into kidney transplant, IgAN trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.4M ($0.50/share) vs $2.6M loss in Q2 2020; R&D spend rose to $4.2M from $0.8M.","Cash $101.1M as of June 30, 2021; company expects to fund operations into 2023.","Health Canada cleared clinical trial of AT-1501 for kidney transplant rejection; initiation in Q4, data late 2022.","FDA agreed on preclinical renal transplant study of AT-1501 monotherapy in 4 non-human primates; data mid-2022.","Plans to develop AT-1501 for IgA nephropathy (IgAN), Phase 2 trial expected to start in Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424779,"accession_number":"0001564590-21-039644","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eledon Pharma announces resignation of Principal Accounting Officer, appoints Paul Little as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Kuwahara resigned as SVP, Finance & Administration and Principal Accounting Officer effective July 31, 2021.","Paul Little, current CFO and Principal Financial Officer, appointed as Principal Accounting Officer effective same date.","No family relationships or arrangements were disclosed in connection with the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424778,"accession_number":"0001564590-21-035584","cik":1404281,"company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","form_type":"8-K","filed_at":"2021-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eledon appoints Jan Hillson, M.D. as independent director; grants option for 40,000 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jan Hillson, M.D. appointed to Eledon board effective July 1, 2021; qualifies as independent under Nasdaq rules.","Received option to buy 40,000 shares at $7.68 per share; vests 20,000 on first anniversary, 20,000 on second anniversary.","Dr. Hillson will enter Eledon's standard indemnification agreement; no family relationships with officers/directors.","No arrangements or understandings with any other person regarding her appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292155907.43461543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-02T23:59:59+00:00|424778"}